Single‐center study to determine the safety and efficacy of CT‐707 in Chinese patients with advanced anaplastic lymphoma kinase‐rearranged non‐small‐cell lung cancer

INTRODUCTION: It has been proven that ALK‐rearranged non‐small cell lung cancer (NSCLC) is sensitive to ALK inhibitors while the chemotherapy resistance is unavoidable. In this study, safety and antitumor activity of the novel ALK inhibitor (ALKi) CT‐707 were evaluated in Chinese patients with advan...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Peng, Zhang, Xiaotong, Yang, Dongliang, Wang, Hanping, Si, Xiaoyan, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7180692/
https://www.ncbi.nlm.nih.gov/pubmed/32181989
http://dx.doi.org/10.1111/1759-7714.13376

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7180692/
https://www.ncbi.nlm.nih.gov/pubmed/32181989
http://dx.doi.org/10.1111/1759-7714.13376

Ejemplares similares